BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25336937)

  • 21. The impact of coexisting COPD on survival of patients with early-stage non-small cell lung cancer undergoing surgical resection.
    Zhai R; Yu X; Shafer A; Wain JC; Christiani DC
    Chest; 2014 Feb; 145(2):346-353. PubMed ID: 24008835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
    Pirker R; Pereira JR; von Pawel J; Krzakowski M; Ramlau R; Park K; de Marinis F; Eberhardt WE; Paz-Ares L; Störkel S; Schumacher KM; von Heydebreck A; Celik I; O'Byrne KJ
    Lancet Oncol; 2012 Jan; 13(1):33-42. PubMed ID: 22056021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breathlessness, functional status, distress, and palliative care needs over time in patients with advanced chronic obstructive pulmonary disease or lung cancer: a cohort study.
    Weingaertner V; Scheve C; Gerdes V; Schwarz-Eywill M; Prenzel R; Bausewein C; Higginson IJ; Voltz R; Herich L; Simon ST; ;
    J Pain Symptom Manage; 2014 Oct; 48(4):569-81.e1. PubMed ID: 24613784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Third-line therapy in advanced non-small cell lung cancer.
    Ying Geng Z; Chang Jiao S; Cui Liu S; Li Y; Feng Liu Z; Qing Zhang G; Jie Wang L; Qu F
    J BUON; 2013; 18(4):899-907. PubMed ID: 24344015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival associated with chronic obstructive pulmonary disease among SEER-Medicare beneficiaries with non-small-cell lung cancer.
    Shah S; Blanchette CM; Coyle JC; Kowalkowski M; Arthur ST; Howden R
    Int J Chron Obstruct Pulmon Dis; 2019; 14():893-903. PubMed ID: 31118599
    [No Abstract]   [Full Text] [Related]  

  • 26. Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease.
    Bugge A; Lund MB; Brunborg C; Solberg S; Kongerud J
    Ann Thorac Surg; 2016 Jun; 101(6):2125-31. PubMed ID: 27016839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of COPD on symptoms, quality of life and prognosis in patients with advanced non-small cell lung cancer.
    Yi YS; Ban WH; Sohng KY
    BMC Cancer; 2018 Oct; 18(1):1053. PubMed ID: 30373585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COPD is commonly underdiagnosed in patients with lung cancer: results from the RECOIL study (retrospective study of COPD infradiagnosis in lung cancer).
    Parrón Collar D; Pazos Guerra M; Rodriguez P; Gotera C; Mahíllo-Fernández I; Peces-Barba G; Seijo LM
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1033-1038. PubMed ID: 28408813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preoperative spirometry results as a determinant for long-term mortality after EVAR for AAA.
    Ohrlander T; Dencker M; Acosta S
    Eur J Vasc Endovasc Surg; 2012 Jan; 43(1):43-7. PubMed ID: 22051733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of neuron-specific enolase (NSE) and thymidine kinase (TK) levels in prediction of efficacy ofEGFR-TKIs in patients with advanced-stage NSCLC [corrected].
    Fiala O; Pesek M; Finek J; Benesova L; Minarik M; Bortlicek Z; Topolcan O
    Anticancer Res; 2014 Sep; 34(9):5193-8. PubMed ID: 25202114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical features of lung cancer in smokers with light and mild chronic obstructive pulmonary disease: a retrospective analysis of Japanese surgical cases.
    Kondo R; Yoshida K; Eguchi T; Kobayashi N; Saito G; Hamanaka K; Shiina T; Kurai M
    Eur J Cardiothorac Surg; 2011 Dec; 40(6):1439-43. PubMed ID: 21530296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy.
    Saji H; Tsuboi M; Matsubayashi J; Miyajima K; Shimada Y; Imai K; Kato Y; Usuda J; Kajiwara N; Uchida O; Ohira T; Hirano T; Mukai K; Kato H; Ikeda N
    Anticancer Drugs; 2010 Jan; 21(1):89-93. PubMed ID: 19770636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer.
    Ajimizu H; Ozasa H; Sato S; Funazo T; Sakamori Y; Nomizo T; Kuninaga K; Ogimoto T; Hosoya K; Yamazoe M; Tsuji T; Yoshida H; Itotani R; Ueno K; Kim YH; Muro S; Hirai T
    Sci Rep; 2021 Dec; 11(1):23677. PubMed ID: 34880386
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subsequent chemotherapy improves survival outcome in advanced non-small-cell lung cancer with acquired tyrosine kinase inhibitor resistance.
    Kuo CH; Lin SM; Lee KY; Chung FT; Hsieh MH; Fang YF; Yu CT; Kuo HP
    Clin Lung Cancer; 2010 Jan; 11(1):51-6. PubMed ID: 20085868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic factors and outcomes of unrelated bone marrow transplantation for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) pre-treated with tyrosine kinase inhibitors.
    Yoshimura T; Nakane T; Hirose A; Koh H; Nakamae M; Aimoto M; Nishimoto M; Hayashi Y; Terada Y; Nakamae H; Hino M
    Osaka City Med J; 2013 Jun; 59(1):9-21. PubMed ID: 23909077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.
    Zhang L; Yuan X; Chen Y; Du XJ; Yu S; Yang M
    Gene; 2013 Mar; 517(1):60-4. PubMed ID: 23313300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).
    Gaafar RM; Surmont VF; Scagliotti GV; Van Klaveren RJ; Papamichael D; Welch JJ; Hasan B; Torri V; van Meerbeeck JP;
    Eur J Cancer; 2011 Oct; 47(15):2331-40. PubMed ID: 21802939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy.
    Berghmans T; Lafitte JJ; Thiriaux J; VanHoutte P; Lecomte J; Efremidis A; Koumakis G; Giner V; Richez M; Corhay JL; Wackenier P; Lothaire P; Mommen P; Ninane V; Sculier JP;
    Lung Cancer; 2004 Sep; 45(3):339-48. PubMed ID: 15301874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a patient-centered aggregate score to predict survival after lung resection for non-small cell lung cancer.
    Brunelli A; Salati M; Refai M; Xiumé F; Berardi R; Mazzanti P; Pompili C
    J Thorac Cardiovasc Surg; 2013 Aug; 146(2):385-90.e1-2. PubMed ID: 23651911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy.
    Sörenson S; Fohlin H; Lindgren A; Lindskog M; Bergman B; Sederholm C; Ek L; Lamberg K; Clinchy B
    Eur J Cancer; 2013 Jan; 49(1):115-20. PubMed ID: 22951014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.